Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry

Biologic and targeted synthetic disease-modifying antirheumatic drugs (ts/bDMARDs) play a pivotal role in the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS). Persistence of therapy provides an index of a drug’s overall effectiveness. The objective...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Sci Rep
Autors principals: Prior-Español, A., Sánchez-Piedra, C., Campos, J., Manero, F. J., Pérez-García, C., Bohórquez, C., Busquets-Pérez, N., Blanco-Madrigal, J. M., Díaz-Torne, C., Sánchez-Alonso, F., Mateo, L., Holgado-Pérez, S.
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2021
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8159943/
https://ncbi.nlm.nih.gov/pubmed/34045525
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-90442-w
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars